Faron Pharmaceuticals Oy (FARN) News Today → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free FARN Stock Alerts GBX 127.50 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFaron Pharmaceuticals Oy: Faron Confirms Plans for the Coming Months Under New Leadershipfinanznachrichten.de - April 16 at 8:12 AMFaron Confirms Plans for the Coming Months Under New Leadershipfinance.yahoo.com - April 16 at 3:11 AMInside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AMLfinance.yahoo.com - March 18 at 1:55 PMFaron Pharmaceuticals reports promising phase 1 results from BEXMAB studyfinance.yahoo.com - March 18 at 8:55 AMFaron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimabfinance.yahoo.com - March 14 at 7:43 AMFaron’s Financial Statement Release January 1 to December 31, 2023finance.yahoo.com - March 13 at 10:09 AMFaron Pharma secures €3.2 million convertible loanuk.investing.com - March 4 at 7:12 AMNasdaq Helsinki Ltd: THE SHARES OF FARON PHARMACEUTICALS LTD. GIVEN OBSERVATION STATUSfinanznachrichten.de - February 19 at 10:36 AMFaron Pharmaceuticals Oy (FARN)uk.investing.com - February 1 at 8:16 AMFaron Pharmaceuticals Oy: Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Populationfinanznachrichten.de - January 25 at 8:47 AMDetailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Populationfinance.yahoo.com - January 25 at 3:44 AMFaron Pharmaceuticals Oy (FARN.L)finance.yahoo.com - January 23 at 2:58 AMFaron Pharmaceuticals Oy: Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trialfinanznachrichten.de - January 11 at 9:15 AMFaron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 8:06 AMFaron Pharmaceuticals presents "very positive" Phase 1 data at ASH Conferencefinance.yahoo.com - December 11 at 1:28 PMFaron Pharmaceuticals hails positive results of cancer drug triallse.co.uk - December 11 at 8:28 AMInside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - December 11 at 3:27 AMFaron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicinefinance.yahoo.com - December 7 at 8:03 AMFaron Pharmaceuticals Oy FARNmorningstar.com - November 24 at 1:03 PMFaron Pharmaceuticals initiates second phase of BEXMAB studyfinance.yahoo.com - November 6 at 1:27 PMFaron Pharmaceuticals Oy's (LON:FARN) last week's 11% decline must have disappointed individual investors who have a significant stakefinance.yahoo.com - November 6 at 8:26 AMFaron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meetingfinance.yahoo.com - November 2 at 10:22 AMFaron Pharma raises €7.1m as cancer study continues apaceproactiveinvestors.com - October 27 at 10:32 AMInside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Registerfinance.yahoo.com - October 27 at 10:32 AMFaron Pharmaceuticals' chief speaks after latest promising BEXMAB trial dataproactiveinvestors.com - October 16 at 10:00 AMFaron Pharma data 'extremely encouraging', says CEOproactiveinvestors.com - October 11 at 1:53 PMFaron Pharmaceuticals data 'highly encouraging', say bankproactiveinvestors.com - October 11 at 8:00 AMInside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patientsfinance.yahoo.com - October 11 at 8:00 AMFaron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Next 6-9 Monthsfinance.yahoo.com - October 3 at 9:20 AMBreakeven On The Horizon For Faron Pharmaceuticals Oy (LON:FARN)finance.yahoo.com - September 26 at 8:14 AMFaron Pharmaceuticals Ltd Results of the Extraordinary General Meetingmarkets.businessinsider.com - September 22 at 10:15 PMFaron Pharmaceuticals Announces Board Changesfinance.yahoo.com - September 22 at 12:14 PMFaron Pharmaceuticals Ltd Results of the Extraordinary General Meetingfinance.yahoo.com - September 22 at 7:14 AMBRIEF-Faron Pharmaceuticals Appoints Birge Berns As Interim Chief Medical Officerreuters.com - September 21 at 7:24 AMFaron Pharma appoints new chief medical officerproactiveinvestors.com - September 21 at 7:24 AMFaron Pharmaceuticals Oy: Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officerfinanznachrichten.de - September 21 at 7:24 AMFaron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officerfinance.yahoo.com - September 21 at 2:24 AMFaron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 3:54 AMFaron Pharmaceuticals kicks off second half with FDA announcementfinance.yahoo.com - September 1 at 8:44 AMFaron Pharmaceuticals Oy's (LON:FARN) Intrinsic Value Is Potentially 98% Above Its Share Pricefinance.yahoo.com - August 30 at 6:26 AMFaron Pharmaceuticals Oy: Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemiafinanznachrichten.de - August 29 at 5:20 AMFaron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemiafinance.yahoo.com - August 29 at 12:20 AMFaron Reports Half-Year Financial Results, January 1 – June 30, 2023finance.yahoo.com - August 29 at 12:20 AMFaron Pharmaceuticals Notice of Half-Year Financial Resultsfinance.yahoo.com - August 4 at 4:49 PMFaron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conferencefinance.yahoo.com - August 2 at 12:02 PMFaron Pharmaceuticals hoping for first filing of BLA in H1 2025finance.yahoo.com - July 25 at 8:45 AMFaron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Updatefinance.yahoo.com - July 19 at 8:32 AMFaron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDSfinance.yahoo.com - July 19 at 8:32 AMFARON.HE - Faron Pharmaceuticals Oyuk.finance.yahoo.com - June 21 at 6:34 PMNew biomarker data from BEXMAB study at EHA2023finance.yahoo.com - June 9 at 4:16 AM Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> FARN Media Mentions By Week FARN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FARN News Sentiment▼0.000.32▲Average Medical News Sentiment FARN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FARN Articles This Week▼01▲FARN Articles Average Week Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Scancell News Futura Medical News Poolbeg Pharma News e-therapeutics News Arecor Therapeutics News Redx Pharma News C4X Discovery News OKYO Pharma News Sareum News Hemogenyx Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:FARN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
